Riskpilot← Back to searchSign inGet full accessErol Aktiebolag
ABActiveOrg 5565285672Andv 8Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19962 employees
Revenue 2024
SEK 3M
-21% vs 2023
EBITDA margin
-63.5%
+5% vs 2023
Equity ratio
95.1%
Financial strength
Net profit 2024
SEK -1,9M
+46% vs 2023
| Revenue | SEK 3M | -21% |
| EBITDA | SEK -1,9M | +5% |
| Net profit | SEK -1,9M | +46% |
| Total assets | SEK 12,9M | -21% |
| Equity | SEK 12,3M | -14% |
| Employees | 2 | — |
Legal name
Erol Aktiebolag
Org number
5565285672
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17 januari 1996
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall driva marknadsföring och försäljning av läkemedel och liknade produkter samt idka därmed förenlig verksamhet.
Address
Andv 8
Phone
+46406880969
Email
david.erlich@erol.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 766 | 3 281 | 3 256 | 3 849 | 3 034 |
| Staff expenses | — | — | −1 515 | −1 641 | −1 627 |
| EBITDA | −723 | −1 577 | −1 795 | −2 019 | −1 927 |
| Depreciation & amort. | −707 | −848 | −848 | −848 | −855 |
| EBIT | −1 430 | −2 425 | −2 644 | −2 868 | −2 782 |
| Net financials | 138 | 943 | 164 | −607 | 920 |
| Profit before tax | −210 | 60 | −610 | −3 475 | −1 862 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −210 | 60 | −610 | −3 475 | −1 862 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 26 592 | 21 680 | 19 252 | 16 356 | 12 949 |
| Equity | 21 915 | 18 826 | 18 036 | 14 371 | 12 309 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 265 | 984 | 1 216 | 1 985 | 640 |
| Total debt | 1 265 | 984 | 1 216 | 1 985 | 640 |
EBITDA margin
-63.5%
This company
15.8%
Market median
-502% vs market
20202024
Equity ratio
95.1%
This company
38.2%
Market median
+149% vs market
20202024
Return on equity
-15.1%
This company
18.4%
Market median
-182% vs market
20202024
Net profit margin
-61.4%
This company
8.1%
Market median
-858% vs market
20202024
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PA | Audit | 2021 |
LD Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
PM | Audit | 2021 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Deputy Board Member | 2021 | |
| Former (1) | ||
| Chairman | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Erol Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Magnus Lennart Larsson | Audit | 0 companies |
| Per Axel Håkan Ahlquist | Audit | 0 companies |
| Lajb David Erlich | Chief Executive Officer | 0 companies |
| Seppo Vilhelm Vertanen | Chairman | 0 companies |
| Anita Erlich | Deputy Board Member | 0 companies |
| Anita Erlich | Deputy Board Member | 0 companies |